Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two‐year follow‐up of a …
H Kantarjian, R Pasquini, V Lévy… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: In patients with chronic‐phase chronic myeloid leukemia (CP‐CML),
imatinib resistance is of increasing importance. Imatinib dose escalation was the main …
imatinib resistance is of increasing importance. Imatinib dose escalation was the main …
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
G Rosti, F Palandri, F Castagnetti… - Blood, The Journal …, 2009 - ashpublications.org
Nilotinib has a higher binding affinity and selectivity for BCR-ABL with respect to imatinib
and is an effective treatment of chronic myeloid leukemia (CML) after imatinib failure. In a …
and is an effective treatment of chronic myeloid leukemia (CML) after imatinib failure. In a …
Drugging the addict: non‐oncogene addiction as a target for cancer therapy
R Nagel, EA Semenova, A Berns - EMBO reports, 2016 - embopress.org
Historically, cancers have been treated with chemotherapeutics aimed to have profound
effects on tumor cells with only limited effects on normal tissue. This approach was followed …
effects on tumor cells with only limited effects on normal tissue. This approach was followed …
Harmonization of molecular monitoring of CML therapy in Europe
MC Müller, NCP Cross, P Erben, T Schenk, B Hanfstein… - Leukemia, 2009 - nature.com
The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib
has prompted the need for accurate methods to monitor response at levels below the …
has prompted the need for accurate methods to monitor response at levels below the …
Liquid biopsy in lymphoma: Molecular methods and clinical applications
M Cirillo, AFM Craig, S Borchmann, DM Kurtz - Cancer treatment reviews, 2020 - Elsevier
In this article, we broadly review the application of cfDNA analysis to the diagnosis and
management of lymphoma. We introduce the advantages of cfDNA measurement over …
management of lymphoma. We introduce the advantages of cfDNA measurement over …
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
JP Radich, KJ Kopecky, FR Appelbaum… - Blood, The Journal …, 2012 - ashpublications.org
Tyrosine kinase inhibitor therapy with imatinib (IM), dasatinib (DAS), or nilotinib is very
effective in chronic-phase chronic myeloid leukemia. Two hundred fifty-three patients with …
effective in chronic-phase chronic myeloid leukemia. Two hundred fifty-three patients with …
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome …
DJ DeAngelo, RM Stone, ML Heaney, SD Nimer… - Blood, 2006 - ashpublications.org
Abstract Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III
receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor …
receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor …
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre …
M Bocchia, S Gentili, E Abruzzese, A Fanelli, F Iuliano… - The Lancet, 2005 - thelancet.com
Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
Discontinuation of imatinib therapy after achieving a molecular response
J Cortes, S O'Brien, H Kantarjian - Blood, 2004 - ashpublications.org
Imatinib has become standard therapy for patients with chronic myelogenous leukemia
(CML). A complete cytogenetic response can be achieved in 75% to 90% of patients treated …
(CML). A complete cytogenetic response can be achieved in 75% to 90% of patients treated …